Explore By Subject Area   

Immuno-Oncology 360°

Date: Mar 24, 2025 - Mar 26, 2025

Location: Boston, MA

10th Annual:
​​​​​​​Reporting on the Latest Advancements and Data in IO

Immuno-Oncology 360° offered an unparalleled opportunity to hear from stakeholders representing both the science and business communities who reported on the latest data impacting ​​​​​​​​​​​​​​IO to fight a wider range of cancers.

2024 Keynotes & VIP Speakers

CEO Keynote:
​​​​​​​Future of ​​​​​TIL Therapy

image placeholder

Patrick Hwu, MD
 Moffitt Cancer Center

Neoadjuvant Keynote:
Strategies to Assess IO Candidates

image placeholder

​​​​​​​Laura Esserman, MD, MBA

Clinical Evolution of IO Keynote

image placeholder

Taha Merghoub, PhD
Weill Cornell Medicine

Analyst Keynote:
Top 10 IO ​​​​​​​Recommendations

image placeholder

​​​​​​​Andrew Baum, MD

Data Mining & AI Keynote: 
​​​​​​​Clinical and Translational Data to Discovery and Trial Design

image placeholder

​​​​​​​Ira Mellman, PhD

Cancer Vaccines Keynote:
​​​​​​​What Has Worked, What Hasn't and What's Next

image placeholder

​​​​​​​Margaret Callahan, MD, PhD
University of Connecticut

Cell Therapy Keynote: 
​​​​​​​Discoveries from the Clinic that Help Inform Cell Therapy

image placeholder

Kristen Hege, MD 
Independent Board Member at Adaptimmune, Mersana & Graphite Bio

Lessons Learned to Help Advance IO

image placeholder

Jason Luke, MD, FACP
UPMC Hillman Cancer

Generative AI's Impact on
​​​​​​​IO Drug Development

image placeholder

​​​​​​​Alexandra Snyder, MD
Generate Bio

Public Investing in a Difficult IPO Market

image placeholder

​​​​​​​Rajiv Kaul
Fidelity Investments

image placeholder

IO360° Delivers 3 Key Benefits

1. Access to KOLs and stakeholders in the science and business communities, reporting on cutting-edge research and trends shaping IO technology, investment, and innovation

2. Presentations featuring 100+ talks on the latest innovative research delivered by international leaders from academia, investors, and industry representatives
3. 10+ hours of networking and business development opportunities to connect with 600+ attendees who specialize in cancer immunotherapy

2024 Key Topics

  Biomarkers/Assay Development 

Discovery / Preclinical

Imaging Advancements

Payload Modification

Translational Science

AI Enablement for IO

Cancer Vaccines

Cell Therapy

Clinical Developments

Neoadjuvant/Adjuvant Therapy

Business and Investing Aspects

Networking and Business Opportunities

Partnering/One-on-One Meetings:

​​​​​​​ • Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk

Scheduled Networking:

IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
• Early evening organized historical walks of downtown Brooklyn​​​​​​​

2024 Event Features

image placeholder
image placeholder
image placeholder
image placeholder

Who Attends

Companies Attending:

• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• Boehringer Ingelheim​​​​​​​
• City of Hope

• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center​​​​​​​
• Merck
• Moderna
• Morgan Stanley

• Mount Sinai
MPM BioImpact
• Novartis
• OrbiMed
​​​​​​​• RA Capital
• Regeneron
​​​​​​​• Stanford University
• Stifel
​​​​​​​• Takeda
• And More!

"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks ​​​​​​​participating who are not traditionally talking to one another on a daily basis.- Dr Roy Baynes, Eikon Therapeutics​​​​​​​

Bringing in the Voice of the Patient

image placeholder

Kelly Spill Bonito
Patient Advocate

The Personal Impact of an
Immunotherapy Trial 

We were honored to welcome Kelly Spill Bonito, a stage 3 colorectal cancer survivor, who shares her extraordinary journey through an immunotherapy clinical trial, recounting how it has not only saved her life but also restored her ability to have and raise her children.

2024 Featured Speakers

image placeholder

Hope Rugo, MD
City of Hope

image placeholder

Judd Englert, MD, PhD

image placeholder

Moitreyee Chatterjee-Kishore, PhD
Astellas Pharma US

image placeholder

Gregory Lubiniecki, MD

image placeholder

Olivier Rixe, MD, PhD

image placeholder

Marisa Dolled-Filhart, PhD

image placeholder

Mark DeMario, MD, MPH
BioNTech US

image placeholder

Edith Perez, MD
Bolt Therapeutics

image placeholder

Shubh Goel

image placeholder

Robert Meehan, MD

image placeholder

Sergio Quezada, PhD
University College London Cancer Institute / Achilles Therapeutics

image placeholder

Harpreet Singh, PhD

image placeholder

Strategic Advisors

2024 Sponsors

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.